Elvitegravir (BioDeep_00000706865)
代谢物信息卡片
Elvitegravir(GS-9137,JTK-303)
化学式: C23H23ClFNO5 (447.12487100000004)
中文名称: 埃替拉韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
InChI: InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AJ - Integrase inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D004791 - Enzyme Inhibitors > D019429 - Integrase Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:72289
- KEGGdrug: D06677
- PubChem: 5277135
- DrugBank: DB09101
- ChEMBL: CHEMBL204656
- CAS: 697761-98-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Journal of acquired immune deficiency syndromes (1999).
2022 10; 91(S1):S8-S15. doi:
10.1097/qai.0000000000003040. [PMID: 36094509] - Jen-Yu Hsu, Hsin-Yun Sun, Tan-Wen Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Yu-Shan Huang, Ching-Yu Hsiao, Yi-Ching Su, Wen-Chun Liu, Shu-Fang Chang, Chien-Ching Hung. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Journal of global antimicrobial resistance.
2022 Jun; 29(?):7-16. doi:
10.1016/j.jgar.2022.02.007. [PMID: 35172201] - Huan Xia, Xiao-Jie Huang, Yue Hu, Li-Ying Gao, Yue Wu, Hao Wu, Zhong-Fang Yan, Ping Ma. Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Chinese medical journal.
2021 Oct; 134(23):2850-2856. doi:
10.1097/cm9.0000000000001824. [PMID: 34653085] - Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
HIV research & clinical practice.
2021 10; 22(5):128-139. doi:
. [PMID: 34551678] - Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, İlyas Dokmetas. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
International journal of STD & AIDS.
2021 05; 32(6):562-569. doi:
10.1177/0956462420983692. [PMID: 33599173] - Yu-Shan Huang, Chien-Yu Cheng, Bo-Huang Liou, Po-Liang Lu, Shu-Hsing Cheng, Yuan-Ti Lee, Chun-Eng Liu, Hsin-Yun Sun, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Mao-Wang Ho, Sung-Hsi Huang, Hung-Chin Tsai, Chen-Hsiang Lee, Chien-Ching Hung. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Journal of acquired immune deficiency syndromes (1999).
2021 04; 86(4):473-481. doi:
10.1097/qai.0000000000002589. [PMID: 33273214] - Guan-Jhou Chen, Yu-Lin Lee, Chen-Hsiang Lee, Hsin-Yun Sun, Chien-Yu Cheng, Hung-Chin Tsai, Sung-Hsi Huang, Yi-Chieh Lee, Min-Han Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Li-Shin Su, Sui-Fang Chang, Hung-Jen Tang, Chien-Ching Hung. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
The Journal of antimicrobial chemotherapy.
2020 10; 75(10):2986-2993. doi:
10.1093/jac/dkaa287. [PMID: 32737511] - Qing Ma, Andrew J Ocque, Gene D Morse, Chelsea Sanders, Alina Burgi, Susan J Little, Scott L Letendre. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2020 08; 71(4):982-988. doi:
10.1093/cid/ciz926. [PMID: 31560741] - Yuqing Gong, Kaining Zhi, Prashanth K B Nagesh, Namita Sinha, Pallabita Chowdhury, Hao Chen, Santhi Gorantla, Murali M Yallapu, Santosh Kumar. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
Viruses.
2020 05; 12(5):. doi:
10.3390/v12050564. [PMID: 32443728] - Rossana Scutari, Claudia Alteri, Ilaria Vicenti, Domenico Di Carlo, Valentina Zuccaro, Francesca Incardona, Vanni Borghi, Antonia Bezenchek, Massimo Andreoni, Andrea Antinori, Carlo Federico Perno, Antonio Cascio, Andrea De Luca, Maurizio Zazzi, Maria Mercedes Santoro. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Journal of global antimicrobial resistance.
2020 03; 20(?):163-169. doi:
10.1016/j.jgar.2019.07.015. [PMID: 31330378] - Po-Hsien Kuo, Hsin-Yun Sun, Yu-Chung Chuang, Pei-Ying Wu, Wen-Chun Liu, Chien-Ching Hung. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2020 Mar; 92(?):71-77. doi:
10.1016/j.ijid.2019.12.029. [PMID: 31884172] - Richard E Haaland, Amy Martin, Tamee Livermont, Jeffrey Fountain, Chuong Dinh, Angela Holder, Lindsey D Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F Kelley. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Journal of acquired immune deficiency syndromes (1999).
2019 11; 82(3):252-256. doi:
10.1097/qai.0000000000002133. [PMID: 31335590] - Hwa-Ping Feng, Zifang Guo, Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Daniel P Dreyer, Robert Valesky, Monika Martinho, Matthew L Rizk, Marian Iwamoto, Wendy W Yeh. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Clinical pharmacology in drug development.
2019 10; 8(7):952-961. doi:
10.1002/cpdd.702. [PMID: 31173673] - Arkaitz Imaz, Jordi Niubó, Mackenzie L Cottrell, Emilia Perez, Angela D M Kashuba, Juan M Tiraboschi, Sandra Morenilla, Benito Garcia, Daniel Podzamczer. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019 09; 69(8):1403-1409. doi:
10.1093/cid/ciy1074. [PMID: 30561517] - Binh Nguyen, Michelle M Foisy, Christine A Hughes. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
The Annals of pharmacotherapy.
2019 08; 53(8):833-844. doi:
10.1177/1060028019830788. [PMID: 30739498] - Dario Cattaneo, Annalisa Ridolfo, Sara Baldelli, Cristina Gervasoni. Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report.
European journal of clinical pharmacology.
2019 Aug; 75(8):1177-1178. doi:
10.1007/s00228-019-02677-2. [PMID: 30982083] - Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonio Di Biagio, Giulia Marchetti, Sergio Lo Caputo, Stefano Rusconi, Nicola Gianotti, Valentina Mazzotta, Giovanni Mazzarello, Andrea Costantini, Antonella Castagna, Andrea Antinori. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
The Journal of antimicrobial chemotherapy.
2019 05; 74(5):1363-1367. doi:
10.1093/jac/dky566. [PMID: 30698801] - J M Llibre, A Montoliu, J M Miró, P Domingo, M Riera, J Tiraboschi, A Curran, F Homar, J Ambrosioni, N Abdulghani, L Force, J Peraire, J Casabona. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
HIV medicine.
2019 03; 20(3):237-247. doi:
10.1111/hiv.12710. [PMID: 30688007] - Claire Guerveno, Stéphanie Raymond, David Metsu, Peggy Gandia, Jacques Izopet, Guillaume Martin-Blondel, Pierre Delobel. HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy.
AIDS (London, England).
2019 03; 33(3):593-594. doi:
10.1097/qad.0000000000002089. [PMID: 30702524] - G Baldin, A Ciccullo, A Capetti, S Rusconi, G Sterrantino, M V Cossu, A Giacomelli, F Lagi, A Latini, P Bagella, A De Luca, S Di Giambenedetto, G Madeddu. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
HIV medicine.
2019 02; 20(2):164-168. doi:
10.1111/hiv.12688. [PMID: 30457197] - Pauline D J Bollen, Marga J A de Graaff-Teulen, Stein Schalkwijk, Nielka P van Erp, David M Burger. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Jan; 1105(?):76-84. doi:
10.1016/j.jchromb.2018.12.008. [PMID: 30572204] - Sai Archana Krovi, Matthew D Gallovic, Austin M Keller, Menakshi Bhat, Pamela Tiet, Naihan Chen, Michael A Collier, Elizabeth G Gurysh, Erica N Pino, Monica M Johnson, M Shamim Hasan Zahid, Mackenzie L Cottrell, Jason R Pirone, Angela D Kashuba, Jesse J Kwiek, Eric M Bachelder, Kristy M Ainslie. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
International journal of pharmaceutics.
2018 Dec; 552(1-2):371-377. doi:
10.1016/j.ijpharm.2018.10.017. [PMID: 30308272] - Jeremiah D Momper, Brookie M Best, Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
AIDS (London, England).
2018 11; 32(17):2507-2516. doi:
10.1097/qad.0000000000001992. [PMID: 30134297] - Takuma Yonemura, Nozomi Okada, Koichi Sagane, Kazuhiro Okamiya, Hideki Ozaki, Toshiaki Iida, Hiroyuki Yamada, Hiroki Yagura. Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study.
Clinical pharmacology in drug development.
2018 09; 7(7):737-743. doi:
10.1002/cpdd.425. [PMID: 29364579] - Sally Hodder, Kathleen Squires, Cissy Kityo, Debbie Hagins, Anchalee Avihingsanon, Anna Kido, Shuping Jiang, Rima Kulkarni, Andrew Cheng, Huyen Cao. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Journal of acquired immune deficiency syndromes (1999).
2018 06; 78(2):209-213. doi:
10.1097/qai.0000000000001663. [PMID: 29481486] - Edwin DeJesus, Bernard Haas, Sorana Segal-Maurer, Moti N Ramgopal, Anthony Mills, Nicolas Margot, Ya-Pei Liu, Tariro Makadzange, Scott McCallister. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
AIDS research and human retroviruses.
2018 04; 34(4):337-342. doi:
10.1089/aid.2017.0203. [PMID: 29368537] - Kiyoto Tsuchiya, Mayu Ohuchi, Naoe Yamane, Hiroaki Aikawa, Hiroyuki Gatanaga, Shinichi Oka, Akinobu Hamada. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Biomedical chromatography : BMC.
2018 Feb; 32(2):. doi:
10.1002/bmc.4058. [PMID: 28762239] - Dario Cattaneo, Davide Minisci, Sara Baldelli, Cristina Mazzali, Andrea Giacomelli, Laura Milazzo, Paola Meraviglia, Chiara Resnati, Giuliano Rizzardini, Emilio Clementi, Massimo Galli, Cristina Gervasoni. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Journal of acquired immune deficiency syndromes (1999).
2018 01; 77(1):86-92. doi:
10.1097/qai.0000000000001558. [PMID: 28961682] - Josep M Llibre, Hortensia Álvarez, Miguel Yzusqui. Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review.
AIDS reviews.
2018; 20(3):158-170. doi:
10.24875/aidsrev.18000006. [PMID: 30264825] - Catia Marzolini, Laurent Decosterd, Ursula Winterfeld, Frédéric Tissot, Katyuska Francini, Thierry Buclin, Françoise Livio. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
British journal of clinical pharmacology.
2017 12; 83(12):2835-2838. doi:
10.1111/bcp.13310. [PMID: 28512794] - Pavan Kumar Prathipati, Subhra Mandal, Gregory Pon, Renuga Vivekanandan, Christopher J Destache. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
Pharmaceutical research.
2017 Dec; 34(12):2749-2755. doi:
10.1007/s11095-017-2255-7. [PMID: 28905173] - Marianne Harris, Bruce Ganase, Birgit Watson, P Richard Harrigan, Julio S G Montaner, Mark W Hull. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
AIDS research and therapy.
2017 Nov; 14(1):59. doi:
10.1186/s12981-017-0185-4. [PMID: 29096670] - Sara Baldelli, Giorgio Marrubini, Dario Cattaneo, Emilio Clementi, Matteo Cerea. Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma.
Therapeutic drug monitoring.
2017 10; 39(5):531-542. doi:
10.1097/ftd.0000000000000428. [PMID: 28650901] - Bassam H Rimawi, Erica Johnson, Augustine Rajakumar, Sijia Tao, Yong Jiang, Scott Gillespie, Raymond F Schinazi, Mark Mirochnick, Martina L Badell, Rana Chakraborty. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Antimicrobial agents and chemotherapy.
2017 06; 61(6):. doi:
10.1128/aac.02213-16. [PMID: 28348149] - Marine Perrier, Charlotte Charpentier, Gilles Peytavin, Minh Lê, Louis Blondel, Benoit Visseaux, Véronique Joly, Adriana Pinto, Sophie Matheron, Yazdan Yazdanpanah, Diane Descamps, Roland Landman. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of antimicrobial chemotherapy.
2017 06; 72(6):1745-1751. doi:
10.1093/jac/dkx018. [PMID: 28186251] - Marco Simiele, Alessandra Ariaudo, Amedeo De Nicolò, Fabio Favata, Martina Ferrante, Chiara Carcieri, Stefano Bonora, Giovanni Di Perri, Antonio De Avolio. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Journal of pharmaceutical and biomedical analysis.
2017 May; 138(?):223-230. doi:
10.1016/j.jpba.2017.02.002. [PMID: 28219799] - A Imaz, J Niubó, A D Kashuba, E Ferrer, C Sykes, N Rozas, L Acerete, A Vila, D Podzamczer. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
HIV medicine.
2017 03; 18(3):225-230. doi:
10.1111/hiv.12417. [PMID: 27477062] - Karl Stefic, Maud Salmona, Marisa Capitao, Marion Splittgerber, Zoha Maakaroun-Vermesse, Marie-Laure Néré, Louis Bernard, Marie-Laure Chaix, Francis Barin, Constance Delaugerre. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
The Journal of antimicrobial chemotherapy.
2017 03; 72(3):850-854. doi:
10.1093/jac/dkw507. [PMID: 27999055] - Arkaitz Imaz, Daniel Podzamczer. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Expert review of anti-infective therapy.
2017 03; 15(3):195-209. doi:
10.1080/14787210.2017.1286736. [PMID: 28117606] - James Milburn, Rachael Jones, Jeremy B Levy. Renal effects of novel antiretroviral drugs.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 03; 32(3):434-439. doi:
10.1093/ndt/gfw064. [PMID: 27190354] - Subhra Mandal, Pavan K Prathipati, Guobin Kang, You Zhou, Zhe Yuan, Wenjin Fan, Qingsheng Li, Christopher J Destache. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
AIDS (London, England).
2017 02; 31(4):469-476. doi:
10.1097/qad.0000000000001349. [PMID: 28121666] - Nicola Squillace, Elena Ricci, Tiziana Quirino, Andrea Gori, Alessandra Bandera, Laura Carenzi, Giuseppe Vittorio De Socio, Giancarlo Orofino, Canio Martinelli, Giordano Madeddu, Stefano Rusconi, Paolo Maggi, Benedetto Maurizio Celesia, Laura Cordier, Francesca Vichi, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Giovanni Francesco Pellicanò, Paolo Bonfanti. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
PloS one.
2017; 12(6):e0179254. doi:
10.1371/journal.pone.0179254. [PMID: 28632758] - Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, Natella Rakhmanina, Mohammed Rassool, Rana Chakraborty, Jagmohan Batra, Pope Kosalaraksa, Wicharn Luesomboon, Danielle Porter, Yongwu Shao, Michael Myers, Lillian Ting, Devi SenGupta, Erin Quirk, Martin S Rhee. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
The lancet. HIV.
2016 12; 3(12):e561-e568. doi:
10.1016/s2352-3018(16)30121-7. [PMID: 27765666] - Kathleen Squires, Cissy Kityo, Sally Hodder, Margaret Johnson, Evgeny Voronin, Debbie Hagins, Anchalee Avihingsanon, Ellen Koenig, Shuping Jiang, Kirsten White, Andrew Cheng, Javier Szwarcberg, Huyen Cao. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
The lancet. HIV.
2016 09; 3(9):e410-e420. doi:
10.1016/s2352-3018(16)30016-9. [PMID: 27562742] - Ricardo Moure, Pere Domingo, José M Gallego-Escuredo, Joan Villarroya, Maria Del Mar Gutierrez, Maria G Mateo, Joan C Domingo, Marta Giralt, Francesc Villarroya. Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines.
Antiviral research.
2016 08; 132(?):59-65. doi:
10.1016/j.antiviral.2016.05.013. [PMID: 27216995] - Sujan Dilly Penchala, Sandra Fawcett, Laura Else, Deirdre Egan, Alieu Amara, Emilie Elliot, Elizabeth Challenger, David Back, Marta Boffito, Saye Khoo. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1027(?):174-80. doi:
10.1016/j.jchromb.2016.05.040. [PMID: 27290668] - Catalina Barceló, Frédéric Gaspar, Manel Aouri, Alice Panchaud, Margalida Rotger, Monia Guidi, Matthias Cavassini, Thierry Buclin, Laurent A Decosterd, Chantal Csajka. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
The Journal of antimicrobial chemotherapy.
2016 07; 71(7):1933-42. doi:
10.1093/jac/dkw050. [PMID: 27029846] - Sarah L Greig, Emma D Deeks. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Drugs.
2016 Jun; 76(9):957-68. doi:
10.1007/s40265-016-0586-z. [PMID: 27189707] - Thai Nguyen, Ian McNicholl, Joseph M Custodio, Javier Szwarcberg, David Piontkowsky. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
AIDS reviews.
2016 Apr; 18(2):101-11. doi:
. [PMID: 27196356] - Emilie Elliot, Alieu Amara, Akil Jackson, Graeme Moyle, Laura Else, Saye Khoo, David Back, Andrew Owen, Marta Boffito. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
The Journal of antimicrobial chemotherapy.
2016 Apr; 71(4):1031-6. doi:
10.1093/jac/dkv425. [PMID: 26679246] - Stein Schalkwijk, Angela Colbers, Deborah Konopnicki, Rick Greupink, Frans G M Russel, David Burger. First reported use of elvitegravir and cobicistat during pregnancy.
AIDS (London, England).
2016 Mar; 30(5):807-8. doi:
10.1097/qad.0000000000000976. [PMID: 26913711] - Nicolas A Margot, Kathryn M Kitrinos, Marshall Fordyce, Scott McCallister, Michael D Miller, Christian Callebaut. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
HIV clinical trials.
2016 Mar; 17(2):78-87. doi:
10.1080/15284336.2016.1142731. [PMID: 26892863] - Christoph D Spinner, Kristina E Kern, Alexander Zink, Eva Wolf, Annamaria Balogh, Sebastian Noe, Alexander Von Werder, Christiane Schwerdtfeger, Roland M Schmid, Roman Iakoubov. Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.
Antiviral therapy.
2016; 21(7):627-631. doi:
10.3851/imp3049. [PMID: 27050630] - Stefano Bonora, Andrea Calcagno, Alice Trentalange, Giovanni Di Perri. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Expert opinion on pharmacotherapy.
2016; 17(3):409-19. doi:
10.1517/14656566.2016.1129401. [PMID: 26642079] - Jannik Fonager, Jonas T Larsson, Christian Hussing, Frederik Neess Engsig, Claus Nielsen, Thea Kølsen Fischer. Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2015 Dec; 73(?):95-100. doi:
10.1016/j.jcv.2015.11.009. [PMID: 26587787] - Elizabeth M Sherman, Marylee V Worley, Nathan R Unger, Timothy P Gauthier, Jason J Schafer. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Clinical therapeutics.
2015 Sep; 37(9):1876-93. doi:
10.1016/j.clinthera.2015.07.022. [PMID: 26319088] - Paul E Sax, David Wohl, Michael T Yin, Frank Post, Edwin DeJesus, Michael Saag, Anton Pozniak, Melanie Thompson, Daniel Podzamczer, Jean Michel Molina, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade-Villanueva, Gordon Crofoot, Joseph M Custodio, Andrew Plummer, Lijie Zhong, Huyen Cao, Hal Martin, Christian Callebaut, Andrew K Cheng, Marshall W Fordyce, Scott McCallister. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet (London, England).
2015 Jun; 385(9987):2606-15. doi:
10.1016/s0140-6736(15)60616-x. [PMID: 25890673] - Ivana Massud, Amy Martin, Chuong Dinh, James Mitchell, Leecresia Jenkins, Walid Heneine, Chou-Pong Pau, J Gerardo García-Lerma. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
The Journal of antimicrobial chemotherapy.
2015 May; 70(5):1473-81. doi:
10.1093/jac/dku556. [PMID: 25630643] - Joanne D Stekler, Jennifer McKernan, Ross Milne, Kenneth A Tapia, Kateryna Mykhalchenko, Sarah Holte, Janine Maenza, Claire E Stevens, Susan E Buskin, James I Mullins, Lisa M Frenkel, Ann C Collier. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
Antiviral therapy.
2015; 20(1):77-80. doi:
10.3851/imp2780. [PMID: 24831260] - Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki, Shigeru Miki, Chiaki Wakasa-Morimoto, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A Johns, Mark R Underwood, Edward P Garvey, Akihiko Sato, Tamio Fujiwara. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Antimicrobial agents and chemotherapy.
2015 Jan; 59(1):397-406. doi:
10.1128/aac.03909-14. [PMID: 25367908] - Antonella Castagna, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert Grossberg, Jean-Michel Molina, Julie Chas, Jacques Durant, Santiago Moreno, Manuela Doroana, Mounir Ait-Khaled, Jenny Huang, Sherene Min, Ivy Song, Cindy Vavro, Garrett Nichols, Jane M Yeo. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
The Journal of infectious diseases.
2014 Aug; 210(3):354-62. doi:
10.1093/infdis/jiu051. [PMID: 24446523] - Anton Pozniak, Martin Markowitz, Anthony Mills, Hans-Juergen Stellbrink, Antonio Antela, Pere Domingo, Pierre-Marie Girard, Keith Henry, Thai Nguyen, David Piontkowsky, Will Garner, Kirsten White, Bill Guyer. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
The Lancet. Infectious diseases.
2014 Jul; 14(7):590-9. doi:
10.1016/s1473-3099(14)70796-0. [PMID: 24908550] - Jose R Arribas, Gilles Pialoux, Joseph Gathe, Giovanni Di Perri, Jacques Reynes, Pablo Tebas, Thai Nguyen, Ramin Ebrahimi, Kirsten White, David Piontkowsky. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
The Lancet. Infectious diseases.
2014 Jul; 14(7):581-9. doi:
10.1016/s1473-3099(14)70782-0. [PMID: 24908551] - Joseph M Custodio, Hui Wang, Jia Hao, Eve-Irene Lepist, Adrian S Ray, Jessica Andrews, Kah Hiing J Ling, Andrew Cheng, Brian P Kearney, Srinivasan Ramanathan. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Journal of clinical pharmacology.
2014 Jun; 54(6):649-56. doi:
10.1002/jcph.256. [PMID: 24375014] - Joseph M Custodio, Martin Rhee, Gong Shen, Kah Hiing J Ling, Brian P Kearney, Srinivasan Ramanathan. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.
Antimicrobial agents and chemotherapy.
2014 May; 58(5):2564-9. doi:
10.1128/aac.02180-13. [PMID: 24550332] - C Reviriego. Elvitegravir for the treatment of HIV infection.
Drugs of today (Barcelona, Spain : 1998).
2014 Mar; 50(3):209-17. doi:
10.1358/dot.2014.50.3.2122120. [PMID: 24696866] - Christian Manzardo, José M Gatell. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
AIDS reviews.
2014 Jan; 16(1):35-42. doi:
NULL. [PMID: 24584107] - Zoubir Djerada, Catherine Feliu, Claire Tournois, Damien Vautier, Laurent Binet, Arnaud Robinet, Hélène Marty, Claire Gozalo, Denis Lamiable, Hervé Millart. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Journal of pharmaceutical and biomedical analysis.
2013 Dec; 86(?):100-11. doi:
10.1016/j.jpba.2013.08.002. [PMID: 23995753] - Filippo Canducci, Elisa Rita Ceresola, Diego Saita, Antonella Castagna, Nicola Gianotti, Mark Underwood, Roberto Burioni, Adriano Lazzarin, Massimo Clementi. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
The Journal of antimicrobial chemotherapy.
2013 Nov; 68(11):2525-32. doi:
10.1093/jac/dkt220. [PMID: 23798668] - Srinivasan Ramanathan, Anita Mathias, Xuelian Wei, Gong Shen, Joanna Koziara, Andrew Cheng, Brian P Kearney. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.
Journal of acquired immune deficiency syndromes (1999).
2013 Sep; 64(1):45-50. doi:
10.1097/qai.0b013e31829ecd3b. [PMID: 23774876] - Manel Aouri, Alexandra Calmy, Bernard Hirschel, Amalio Telenti, Thierry Buclin, Matthias Cavassini, Andri Rauch, Laurent A Decosterd. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Journal of mass spectrometry : JMS.
2013 May; 48(5):616-25. doi:
10.1002/jms.3200. [PMID: 23674286] - Jan Weber, Justine D Rose, Ana C Vazquez, Dane Winner, Nicolas Margot, Damian J McColl, Michael D Miller, Miguel E Quiñones-Mateu. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
PloS one.
2013; 8(6):e65631. doi:
10.1371/journal.pone.0065631. [PMID: 23776513] - Takashi Kawasuji, Brian A Johns, Hiroshi Yoshida, Teruhiko Taishi, Yoshiyuki Taoda, Hitoshi Murai, Ryuichi Kiyama, Masahiro Fuji, Tomokazu Yoshinaga, Takahiro Seki, Masanori Kobayashi, Akihiko Sato, Tamio Fujiwara. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.
Journal of medicinal chemistry.
2012 Oct; 55(20):8735-44. doi:
10.1021/jm3010459. [PMID: 22963135] - Polina German, Hui C Liu, Javier Szwarcberg, Mischa Hepner, Jessica Andrews, Brian P Kearney, Anita Mathias. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.
Journal of acquired immune deficiency syndromes (1999).
2012 Sep; 61(1):32-40. doi:
10.1097/qai.0b013e3182645648. [PMID: 22732469] - Frederick J Lee, Andrew Carr. Tolerability of HIV integrase inhibitors.
Current opinion in HIV and AIDS.
2012 Sep; 7(5):422-8. doi:
10.1097/coh.0b013e328356682a. [PMID: 22886031] - Jeffrey L Lennox. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
Current opinion in HIV and AIDS.
2012 Sep; 7(5):409-14. doi:
10.1097/coh.0b013e3283562a27. [PMID: 22789985] - Jaqueline Souza Cavalcanti, André Minhoto Lança, João Leandro de Paula Ferreira, Margareth da Eira, Daniel Soares de Souza Dantas, Luís Fernando de Macedo Brígido. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Antiviral research.
2012 Jul; 95(1):9-11. doi:
10.1016/j.antiviral.2012.04.007. [PMID: 22564967] - Paul E Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David Wohl, Joel E Gallant, Hui C Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P Kearney, Javier Szwarcberg, Erin Quirk, Andrew K Cheng. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet (London, England).
2012 Jun; 379(9835):2439-2448. doi:
10.1016/s0140-6736(12)60917-9. [PMID: 22748591] - Carolina Garrido, Jorge Villacian, Natalia Zahonero, Theresa Pattery, Federico Garcia, Felix Gutierrez, Estrella Caballero, Margriet Van Houtte, Vincent Soriano, Carmen de Mendoza. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.
Antimicrobial agents and chemotherapy.
2012 Jun; 56(6):2873-8. doi:
10.1128/aac.06170-11. [PMID: 22450969] - Todd Wills, Vivian Vega. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Expert opinion on investigational drugs.
2012 Mar; 21(3):395-401. doi:
10.1517/13543784.2012.658914. [PMID: 22321026] - Nicolas A Margot, Rebecca M Hluhanich, Gregg S Jones, Kristen N Andreatta, Manuel Tsiang, Damian J McColl, Kirsten L White, Michael D Miller. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral research.
2012 Feb; 93(2):288-296. doi:
10.1016/j.antiviral.2011.12.008. [PMID: 22197635] - Jean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, Bonaventura Clotet, Nathan Clumeck, Ya-Pei Liu, Lijie Zhong, Nicolas Margot, Andrew K Cheng, Steven L Chuck. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
The Lancet. Infectious diseases.
2012 Jan; 12(1):27-35. doi:
10.1016/s1473-3099(11)70249-3. [PMID: 22015077] - Xiaoju Ni, Safwat Abdel-Azeim, Elodie Laine, Rohit Arora, Osamuede Osemwota, Anne-Geneviève Marcelin, Vincent Calvez, Jean-François Mouscadet, Luba Tchertanov. In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.
Advances in virology.
2012; 2012(?):548657. doi:
10.1155/2012/548657. [PMID: 22829822] - Kundan B Ingale, Manish S Bhatia. HIV-1 integrase inhibitors: a review of their chemical development.
Antiviral chemistry & chemotherapy.
2011 Nov; 22(3):95-105. doi:
10.3851/imp1740. [PMID: 22095518] - Xiao-Ju Ni, Olivier Delelis, Charlotte Charpentier, Alexandre Storto, Gilles Collin, Florence Damond, Diane Descamps, Jean-François Mouscadet. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology.
2011 Aug; 8(?):68. doi:
10.1186/1742-4690-8-68. [PMID: 21854605] - Olivia Goethals, Marcia Van Ginderen, Ann Vos, Maxwell D Cummings, Koen Van Der Borght, Liesbeth Van Wesenbeeck, Maxim Feyaerts, Ann Verheyen, Veerle Smits, Marnix Van Loock, Kurt Hertogs, Dominique Schols, Reginald F Clayton. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Antiviral research.
2011 Aug; 91(2):167-76. doi:
10.1016/j.antiviral.2011.05.011. [PMID: 21669228] - Srinivasan Ramanathan, Anita A Mathias, Polina German, Brian P Kearney. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
Clinical pharmacokinetics.
2011 Apr; 50(4):229-44. doi:
10.2165/11584570-000000000-00000. [PMID: 21348537] - L Van Wesenbeeck, E Rondelez, M Feyaerts, A Verheyen, K Van der Borght, V Smits, C Cleybergh, H De Wolf, K Van Baelen, L J Stuyver. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.
Antimicrobial agents and chemotherapy.
2011 Jan; 55(1):321-5. doi:
10.1128/aac.01733-09. [PMID: 20956600] - Jesse Thompson, Martha MacMillan, Karen Boegler, Charles Wood, John H Elder, Sue VandeWoude. Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements.
PloS one.
2011; 6(8):e24020. doi:
10.1371/journal.pone.0024020. [PMID: 21887365] - Zhiqi Yin, Robert Craigie. Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors.
Viruses.
2010 12; 2(12):2777-81. doi:
10.3390/v2122777. [PMID: 21994639] - Polina German, David Warren, Steve West, James Hui, Brian P Kearney. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Journal of acquired immune deficiency syndromes (1999).
2010 Nov; 55(3):323-9. doi:
10.1097/qai.0b013e3181eb376b. [PMID: 20683270] - Francesca Ceccherini-Silberstein, Isabelle Malet, Lavinia Fabeni, Salvatore Dimonte, Valentina Svicher, Roberta D'Arrigo, Anna Artese, Giosuè Costa, Sara Bono, Stefano Alcaro, Antonella d'Arminio Monforte, Christine Katlama, Vincent Calvez, Andrea Antinori, Anne-Genevieve Marcelin, Carlo-Federico Perno. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
The Journal of antimicrobial chemotherapy.
2010 Nov; 65(11):2305-18. doi:
10.1093/jac/dkq326. [PMID: 20817922] - Juan Reguera, Friedemann Weber, Stephen Cusack. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription.
PLoS pathogens.
2010 Sep; 6(9):e1001101. doi:
10.1371/journal.ppat.1001101. [PMID: 20862319] - Babafemi Taiwo, Robert L Murphy, Christine Katlama. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Drugs.
2010 Sep; 70(13):1629-42. doi:
10.2165/11538020-000000000-00000. [PMID: 20731472] - Francesca Ceccherini-Silberstein, Kurt Van Baelen, Daniele Armenia, Maria Trignetti, Evelien Rondelez, Lavinia Fabeni, Fernanda Scopelliti, Michela Pollicita, Liesbeth Van Wesenbeeck, Veerle Van Eygen, Luca Dori, Loredana Sarmati, Stefano Aquaro, Guido Palamara, Massimo Andreoni, Lieven J Stuyver, Carlo Federico Perno. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Antimicrobial agents and chemotherapy.
2010 Sep; 54(9):3938-48. doi:
10.1128/aac.01720-09. [PMID: 20479206] - Hiroyu Hatano, Harry Lampiris, Signe Fransen, Soumi Gupta, Wei Huang, Rebecca Hoh, Jeffrey N Martin, Jacob Lalezari, David Bangsberg, Christos Petropoulos, Steven G Deeks. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999).
2010 Aug; 54(4):389-93. doi:
10.1097/qai.0b013e3181c42ea4. [PMID: 20300008] - Daniel da Silva, Liesbeth Van Wesenbeeck, Dominique Breilh, Sandrine Reigadas, Guerric Anies, Kurt Van Baelen, Philippe Morlat, Didier Neau, Michel Dupon, Linda Wittkop, Hervé Fleury, Bernard Masquelier. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
The Journal of antimicrobial chemotherapy.
2010 Jun; 65(6):1262-9. doi:
10.1093/jac/dkq099. [PMID: 20388636] - Muhammad Q Fish, Raymond Hewer, Carole L Wallis, Willem D F Venter, Wendy S Stevens, Maria A Papathanasopoulos. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
AIDS research and human retroviruses.
2010 Apr; 26(4):489-93. doi:
10.1089/aid.2009.0249. [PMID: 20377427] - Srinivasan Ramanathan, Samantha Abel, Sarah Tweedy, Steve West, James Hui, Brian P Kearney. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
Journal of acquired immune deficiency syndromes (1999).
2010 Feb; 53(2):209-14. doi:
10.1097/qai.0b013e3181ba4536. [PMID: 19851115]